로딩 중…
지수 로딩 중…
한국파마
032300· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩7,960+2.45%
2026-11-02
Financials
Valuation Metrics
한국파마's Market Cap is ₩868B. At end of 2025 it was ₩1418B. Ranked #1326 of 2,410 in KR market (top 55%), #733 of 1,631 on KOSDAQ (top 45%), #148 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 64%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 86.82B KRW | KR#1,326/2,410 Sec#148/231 |
| Revenue | 93.94B KRW | KR#1,449/2,410 Sec#89/231 |
| Net Income | -773.5M KRW | KR—/2,410 Sec—/231 |
| Total Assets | 130.51B KRW | KR#1,597/2,410 Sec#125/231 |
| Net Assets | 73.62B KRW | KR#1,642/2,410 Sec#135/231 |
| Employees | 284 | KR#831/2,410 Sec#69/231 |
| Value | ||
| P/B | 1.18x | KR#1,664/2,410 Sec#109/231 |
| P/S | 0.92x | KR#1,378/2,410 Sec#80/231 |
| EV/EBITDA | 54.59x | KR#1,375/2,410 Sec#90/231 |
| FCF Yield | 1.65% | KR#1,091/2,410 Sec#74/231 |
| Profitability | ||
| ROE | -1.05% | KR#1,622/2,410 Sec#110/231 |
| ROA | -0.59% | KR#1,627/2,410 Sec#110/231 |
| Op. Margin | 1.78% | KR#1,412/2,410 Sec#99/231 |
| Revenue Growth | 10.08% | KR#887/2,410 Sec#86/231 |
| Earnings Growth | -153.40% | KR#1,205/2,410 Sec#77/231 |
| Financial Health | ||
| Debt Ratio | 77.28% | KR#1,308/2,410 Sec#156/231 |
| Total Debt | 32.86B KRW | KR#1,177/2,410 Sec#86/231 |
| FCF | 1.44B KRW | KR#1,118/2,410 Sec#81/231 |
| Cash | 28.48B KRW | KR#1,037/2,410 Sec#72/231 |
| Current Ratio | 1.58x | KR#1,126/2,410 Sec#123/231 |
| Net Debt/EBITDA | 2.62x | KR#886/2,410 Sec#64/231 |
| Dividend | ||
| Div. Yield | 0.63% | KR#1,238/2,410 Sec#75/231 |
| Div. Growth | 0.00% | KR—/2,410 Sec—/231 |
| Performance | ||
| 1Y Return | -39.83% | KR#1,753/2,410 Sec#146/231 |
| 1M Return | -8.72% | KR#177/2,410 Sec#15/231 |
| From 52W High | -46.76% | KR#1,046/2,410 Sec#73/231 |
| 1Y MDD | -51.74% | KR#1,021/2,410 Sec#81/231 |
| Trading | ||
| Volume | 6,936 shares | KR#1,813/2,410 Sec#184/231 |
| Trading Value | 55.2M KRW | KR#1,540/2,410 Sec#161/231 |
| Foreign Own. | 1.84% | KR#1,683/2,410 Sec#162/231 |
| Per Share | ||
| EPS | -71 KRW | KR—/2,410 Sec—/231 |
| BPS | 6,750 KRW | KR#1,284/2,410 Sec#91/231 |
Company Info
동사는 1974년 민생제약사 인수, 1985년 법인 전환 후 의약품 제조 및 판매를 주요 사업으로 하고 있음. 자체 R&D로 정신신경계, 순환기계, 소화기계, 항생항균 등에 강점이 있으며, 다양한 질환군의 처방 의약품을 제조 및 판매하고 있음. 2018년 신약연구센터 개소, 2021년 연구환경을 개선하고 차별화 제품 발굴, 제네릭에서 신약까지 개발을 확장하고 있음. 한국파마는 1985년에 설립되었으며 경기도 화성시에 본사를 두고 있습니다.